<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fluciclovine F-18: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fluciclovine F-18: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fluciclovine F-18: Drug information</div><div class="clear"></div><div id="topicText">For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F49128711"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Axumin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F46679318"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F46812117"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a242dd7a-63e5-444d-b313-c1b0fb21c573">Diagnostic imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Diagnostic imaging:</b> IV: 370 MBq (10 mCi); begin PET scanning 3 to 5 minutes after completion of fluciclovine F 18 administration.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990761"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>
<div class="block doha drugH1Div" id="F50987780"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>
<div class="block doe drugH1Div" id="F46812118"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. </p></div>
<div class="block adr drugH1Div" id="F46720597"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Erythema at injection site (≤1%), pain at injection site (≤1%)</p></div>
<div class="block coi drugH1Div" id="F46679321"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F46812057"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions including anaphylaxis may occur in patients who receive fluciclovine F 18. Emergency resuscitation equipment and personnel should be immediately available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation accumulation: Fluciclovine F 18 administration contributes to the patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and health care providers. If a CT scan is performed simultaneously as part of the PET procedure, exposure to ionizing radiation will increase in an amount dependent on the CT settings. </p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special Handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority. </p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Imaging interpretation: Localization of prostate cancer recurrence is based on fluciclovine F 18 uptake compared to tissue background. For small lesions (diameter &lt;1 cm), focal update greater than blood pool is considered suspicious for prostate cancer. For larger lesions, uptake equal to or greater than bone marrow is considered suspicious.    </p>
<p style="text-indent:-2em;margin-left:4em;">• Risk for misinterpretation: Image interpretation errors may occur with fluciclovine F 18 PET imaging. A negative image does not rule out the presence of recurrent prostate cancer and a positive image does not confirm the presence of recurrent prostate cancer. The performance of fluciclovine F 18 appears to be affected by PSA levels. Fluciclovine F 18 uptake is not specific for prostate cancer and may occur with other types of cancer and/or with benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation of the suspected recurrence site, is recommended.</p></div>
<div class="block foc drugH1Div" id="F49128712"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Axumin: 335-8200 MBq/mL (9-221 mCi/mL) (1 ea)</p></div>
<div class="block geq drugH1Div" id="F49128714"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F52605649"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Axumin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9-221 mci/mL (per each): $5,760.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F46812122"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer as an intravenous bolus. May administer diluted (in NS) or undiluted. The maximum volume of undiluted fluciclovine F 18 is 5 mL. After administration, flush with NS to ensure full delivery of the dose.</p>
<p style="text-indent:-2em;margin-left:2em;">For imaging, position patient supine with arms above head. Begin PET scanning 3 to 5 minutes after completion of fluciclovine F 18 administration. Image acquisition should start from mid-thigh and proceed to the base of the skull. Typical total scan time is 20 to 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients should not eat or drink for at least 4 hours (other than small amounts of water for taking medications) prior to administration. Advise the patient to avoid any significant exercise for at least 1 day prior to PET imaging. Instruct patients to void ~30 to 60 minutes prior to administration and refrain from voiding until scan is complete.</p>
<p style="text-indent:-2em;margin-left:2em;">Radiopharmaceutical; use appropriate precautions for handling and disposal. When handling and administering, follow appropriate safety measures to minimize radiation exposure during administration; use waterproof gloves and effective shielding, including syringe shields.</p></div>
<div class="block use drugH1Div" id="F46679320"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diagnostic imaging:</b> Positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment</p></div>
<div class="block mst drugH1Div" id="F46679315"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fluciclovine F18 may be confused with florbetaben F18, florbetapir F18, fludeoxyglucose f18, flutemetamol F 18</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F46683175"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F46683172"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F46812055"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Fluciclovine F 18 is not indicated for use in women; animal reproduction studies were not conducted.  </p></div>
<div class="block brc drugH1Div" id="F46812056"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Fluciclovine F 18 is not indicated for use in women; it is not known if fluciclovine F 18 is excreted in breast milk.</p></div>
<div class="block mop drugH1Div" id="F46812125"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs/symptoms of hypersensitivity. </p></div>
<div class="block pha drugH1Div" id="F46812064"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fluciclovine F 18 is a radioactive diagnostic agent; localization of prostate cancer recurrence is based on fluciclovine F 18 uptake in prostate cancer cells in comparison to surrounding background tissue. </p></div>
<div class="block phk drugH1Div" id="F46812072"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Tumor-to-normal tissue contrast is highest 4 to 10 minutes following administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Imaging: A 61% reduction in mean tumor uptake occurs at 90 minutes following administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 14% of the total dose distributed to the liver, 12% to red bone marrow, 7% to lung, 4% to myocardium, 3% to pancreas; with increasing time, fluciclovine F 18 distributes to skeletal muscle. The highest magnitude radiation doses are delivered to the pancreas, cardiac wall, and uterine wall.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, elimination: Physical half-life: 109.7 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (3% [4 hours post-injection]; 5% [24 hours post-injection])</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F50615684"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Axumin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Axumin (fluciclovine F 18) [prescribing information]. Oxford, UK: Blue Earth Diagnostics Ltd; July 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 108367 Version 37.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
